Myeloma Treatment

Novel retinoid AHPN/CD437 induces rapid but incomplete apoptotic response

Published in Blood Weekly, April 10th, 2003

The novel synthetic retinoid AHPN/CD437 triggers a rapid, but incomplete apoptotic response in human myeloma cells.

According to a recent study from France, AHPN/CD437 "appears to possess an apoptotic activity superior to classical retinoids in vitro as in vivo."

"Numerous studies have shown that CD437-induced apoptosis is independent of its nuclear receptor activity, suggesting that CD437 might have a unique mechanism of action," explained B. Joseph and coauthors at the Institut de Recherches sur le Cancer, who conducted a study to "compare CD437- and all-trans retinoic acid (atRA)-induced cell death."

"CD437 provoked a rapid...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2003-04-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry